Prithviraj Bose

Prithviraj Bose is a clinical investigator specializing in myeloproliferative neoplasms with particular expertise in JAK inhibitor therapy for myelofibrosis. He led and contributed to pivotal PERSIST trials evaluating pacritinib for patients with myelofibrosis and severe thrombocytopenia, a population in whom ruxolitinib is often contraindicated. His research characterizes mechanisms of resistance to JAK inhibitors and evaluates rational combination partners including navitoclax. He is an active educator and mentor in the myeloid malignancies field.